#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Warm autoimmune haemolytic anaemia Brain stem glioma Colitis ulcerative Herpes simplex Philadelphia positive chronic myeloid leukaemia Cutaneous T-cell lymphoma stage I Chronic cutaneous lupus erythematosus Alveolar rhabdomyosarcoma Inborn error of metabolism Metastatic gastric cancer Pancreatic neuroendocrine tumour Acute myeloid leukaemia recurrent Haemophagocytic lymphohistiocytosis Encephalopathy neonatal Vulval cancer More trials…

    Learn about Rare Diseases

    Pituitary-dependent Cushing’s syndrome – Trials in Disease Indolent systemic mastocytosis – Basic Information Atypical haemolytic uraemic syndrome – Life with Disease Hyperoxaluria – Treatment Shprintzen-Goldberg syndrome – Treatment Testicular leiomyosarcoma – Trials in Disease Loeys-Dietz syndrome – Trials in Disease Amyotrophic lateral sclerosis – Treatment Pemphigus – Diagnostics Factor IX deficiency – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Hydroxyzine Hydrochloride Mesalazine L-Threonine Imipenem Valoctocogene Roxaparvovec Propylene Glycol Gskvx000000009151 Alternaria Alternata (402) TRONTINEMAB Peposertib Dacarbazine Citrate CLESROVIMAB Xanomeline Tartrate Ezabenlimab Enlicitide Chloride Dactinomycin Febuxostat Hemihydrate Rifamycin Sodium Metolazone Toripalimab More therapies…

    Learn about Your Condition

    Precocious puberty Myxofibrosarcoma Head and neck cancer stage IV Haemofiltration Gallbladder cancer Cold type haemolytic anaemia Neurodevelopmental disorder Normal pressure hydrocephalus Phaeochromocytoma Hodgkin's disease Hypoaesthesia Appendicitis Genital herpes simplex Hepatic angiosarcoma Pyelonephritis acute More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Marginal zone lymphoma

  • A Study of Zanubrutinib for Patients with Anti-MAG Antibody Neuropathy Associated with Blood Disorders or Abnormal Protein in the Blood

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Marginal zone lymphoma
    • Waldenstrom’s macroglobulinaemia
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Zanubrutinib
    Italy

  • Study on Golcadomide and Valemetostat Tosylate for Patients with Relapsed or Refractory Non-Hodgkin Lymphomas

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Valemetostat Tosilate
    • Golcadomide
    • Rituximab
    Denmark France Italy Spain

  • Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Marginal zone lymphoma
    Investigated Drugs:
    • Epcoritamab
    Germany

  • Study of Acalabrutinib and Tafasitamab for Patients with Previously Treated Marginal Zone Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Marginal zone lymphoma
    Investigated Drugs:
    • Tafasitamab
    • Acalabrutinib
    Austria Italy

  • Study of capivasertib tablets in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Marginal zone lymphoma
    • Follicular lymphoma
    • Mantle cell lymphoma
    Investigated Drugs:
    • Capivasertib
    Spain

  • Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ibrutinib
    Czechia France Hungary Italy Poland Spain +1
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!